Market Research Report : Anti Diabetic Pharmaceuticals Market in India 2012


Published on

For the complete report, get in touch with us at :

Published in: Health & Medicine, Business
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Market Research Report : Anti Diabetic Pharmaceuticals Market in India 2012

  1. 1. Insert Cover Image using Slide Master View Do not distortAnti-Diabetic Pharmaceuticals Market - IndiaMarch 2012
  2. 2. Executive Summary Global Market of Anti-diabetic pharmaceuticals is expected to growth at a CAGR of X% for 2010 – 2015 period Market Anti-diabetic pharmaceuticals market in India is valued at INR xx units in 20-- Market is expected to grow at a CAGR of m% from 20-- to 20-- Anti-diabetes therapeutic segment is the second fastest growing segment, after oncology Drivers: Challenges: Increase in the number of diabetic Price regulation in insulin market Drivers and Challenges patients LE Introduction of newer and better drugs Increasing aging population P Use of complementary and alternative medicines Maintainence of healthy lifestyle to avoid diabetes Drug policies covering diabetes Phases of clinical trial M Comprehensive health insurances SARegulation and Approval and licensing of drugs Patents Patents Public Companies Private Companies Company A Company G Company B Company H Competition Company C Company I Company D Company J Company E Company F ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 2
  3. 3. •Introduction•Market Overview•Drivers & Challenges•Government Initiatives•Market Value Chain, Regulation and Patents•Competition•Strategic recommendation ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 3
  4. 4. India’s diabetes market is poised to grow over the coming years Indian Market – Overview Market Size and Growth • India is considered to be one of the most lucrative diabetes markets in the world INR bn • Anti-diabetics represent the second fastest growing y% F therapeutic segment among all the segments ,after 40 E D oncology 30 B C • Market is expected to grow from INR A bn to INR F bn A in 20--, at a CAGR of y% 20 • Biguanides, Gliclazide, Gliclazide with metformine, 10 Rosiglitazone and Pioglitazone are the top selling drugs in Indian market • Human Mixard 30/70 is the largest selling insulin in Indian market It showed largest growth among the top 10 brands in Indian PLE 0 20-- 20--e 20--e 20--e 20--e 20--e M Pharmaceutical market A Growth in therapeutic segments(2010) Market Segmentation oncology diabetes 0 5 10 15 20 25 b 30 S35 a % X1 Drugs Insulin Y2 CVS c X2 CNS d Y1 respiratory e pain f gastro ganti-infectives hSource: ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 4
  5. 5. Drivers & Challenges Challenges Drivers Price regulation in insulin market Increase in the number of diabetic Competition from complementary and patients alternative medicines Introduction of newer and better Maintainence of healthy lifestyle to drugs avoid diabetes Increasing aging population Increase in health insurances ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 5
  6. 6. Various initiatives taken by the government is providing a boost to this market • ICDC ,registered under Planning Commission, Government of India, is the only organisation in India providing doorstep diabetes care • ICDC implements National Doorstep Diabetes Identification and follow-up programme through Grass Root Level NGOs all over India Indian Council for • ICDC affiliates NGOs as Partner Organisation and reach people who are suffering with Diabetes and help Diabetic Care them to control diabetes and live without any complications • ICDC provides free glucometer and 100 Strips to the NGOs to start identifying the diabetes patients even in villages • ICDC is making efforts to provide medical insurance to the diabetes patients through Government of India LE as in the case of family planning insurance scheme MP • National Programme for prevention and Control of Diabetes, Cardiovascular diseases and Stroke (NPCDCS) was started in 2008,with the objective of prevention, diagnosis and early NPCDCS management of diabetes SA • It is already being implemented in 100 most backward and remote districts spread across 21 states • Indian Government plans to extend this programme to all the 650 districts of the country under the 12th five year plan • National Rural Health Mission is providing services for diabetes care in rural India NRHM • Seeks to provide effective healthcare to rural population throughout the country with special focus on 18 statesSource: ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 6
  7. 7. Major Private Companies - Summary PAT 1,000 A Size of the Bubble represents Total Assets 0 in INR XX -1,000 -2,000 -3,000 B PLE -4,000 -5,000 -6,000 -7,000 SAM -8,000 -9,000 C-10,000-11,000 Revenue -500,000 0 500,000 1,000,000 1,500,000 2,000,000 2,500,000 3,000,000 3,500,000 A B C ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 7
  8. 8. Public: Domestic Company – A Company (1/3) Company Information Offices and Centres – India X Road Corporate Address Bangalore Tel No. +91 xx xxxxx xxxxx Fax No. +91 xx xxxxx xxxxx LE Website P Year of Incorporation 19-- M Ticker Symbol xxxxxx A Stock Exchange NNN Products and Services Category Products/Services S City A Head Office CVD, CNS, respiratory, dermatology, Key People Pharmaceutical orthopedics, nutritional, urology, anti- infectives Name Designation Infectious diseases, metabolic diseases, Person M Founder Molecule inflammatory/respiratory diseases, and Person N CFO Development oncology Person O Head Person Q PresidentSource: ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 8
  9. 9. Public: Domestic Company – A Company (2/3) Financial Snapshot Key Ratios Particulars y-o-y change 20-- 20-- 20-- 20-- Revenue Revenue Profit INR mn INR mn Profitability Ratios q Profit / Loss t r p Operating Margin s Net Margin s n r Profit Before Tax Margin LE n p Return on Equity m o 0 q t Return on Capital Employed 0 -m P Return on Working Capital 20-- 20-- 20-- 20-- Return on Assets M Financial Summary Return on Fixed Assets Cost Ratios • The company incurred a net loss of INR xx mn in FY 20--, as compared to net profit of INR yy mn in FY 20-- • The company reported total income of INR xx bn in FY 20--, registering an increase of yy per cent over FY 20-- • The company earned an operating margin of x per cent in FY 20-- a SA Operating costs (% of Sales) Administration costs (% of Sales) Interest costs (% of Sales) Liquidity Ratios Current Ratio decrease of y percentage points over FY 20-- Cash Ratio • The company reported debt to equity ratio of x in FY 20--, an Leverage Ratios increase of y per cent over FY 20-- Debt to Equity Ratio Debt to Capital RatioFinancial Summary Interest Coverage RatioIndicators Present Value Efficiency Ratios Market Capitalization (INR) X mn Fixed Asset Turnover Total Enterprise Value (INR) Y mn Asset Turnover Current Asset Turnover EPS (INR) Z mn Working Capital Turnover PE Ratio (Absolute) A Capital Employed TurnoverSource: Improved Decline ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 9
  10. 10. Public: Domestic Company – A Company (3/3) Key Business Segments Key Geographic Segments m n o x y z x x x LE x x x x y x y y y z y z y z y z y MP z 20-- z 20-- z 20-- z 20-- A 20-- 20-- 20-- 20-- Key Recent Developments Overview Description S News • Company A is an integrated research based company that produces a wide range of generic medicines • Serves customers in over 100 countries with manufacturing facilities in several countries • Launched Drug M for the treatment of diabetes Diabetes Management • Also manufactures Insulin N under its Diabetes management segment • Is making consistent effort for continual improvement in rural areas with respect to accessibility of Key Initiatives medicinesSource: ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 10
  11. 11. Thank you for the attentionThe Anti-Diabetic Pharmaceuticals Market – India report is part of Netscribes’ HealthcareIndustry Series.For more detailed information or customized research requirements please contact:Tamojit RoyE-Mail: sales@netscribes.comNetscribes (India) Pvt. Ltd. is dedicated to disseminating information and providing quick insights on “hot” industries in India and otheremerging markets. Track our new releases and major updates in these industries onAbout NetscribesNetscribes is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment &business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a truevalue proposition that draws upon a vast knowledge base. Netscribes is a one-stop shop designed to fulfil clients’ profitability and growthobjectives.Disclaimer: This report is published for general information only. Although high standards have been used the preparation, Research on India,Netscribes (India) Pvt. Ltd. or “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is thesole property of Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction. ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 11